CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
Transdermal Nicotinedrug
Likely dose
Transdermal Nicotine 21mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01061528
NCT01061528N/ACompleted

Distress Tolerance Treatment for Smoking Cessation

Butler Hospital·interventional·Posted Feb 3, 2010·Updated Oct 16, 2018

In Brief

A clinical study evaluating Transdermal Nicotine for Nicotine Dependence. Completed, enrolled 116 participants across 1 site.

Detailed Summary

The primary purpose of this study is to evaluate the efficacy of a new type of exposure- and acceptance-based smoking cessation treatment vs. standard behavioral smoking cessation treatment, in conjunction with the use of the transdermal nicotine patch. In both treatments, participants will receive one 60-minute individual session, seven 2-hour group sessions and two individual brief telephone contacts over an eight-week period. Both treatments include 8 weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after the treatment sessions have ended. Participants will provide follow-up data with regard to their smoking status through a one-year follow-up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2010
Enrollment StartSep 1, 2009
Primary CompletionAug 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.4 years ago

Interventions

Transdermal Nicotinedrug

Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.